Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announced the granting of a patent for its anti-Pseudomonas aeruginosa phages by the Chinese patent office. This second patent in China, following the one granted in December for its anti-Staphylococcus aureus phages, gives the Company protection until the end of 2034 on this large market.
Guy-Charles Fanneau de La Horie, Chairman of the Executive Board of Pherecydes Pharma, said: “Antibiotic resistance directly caused 1,270,000 deaths worldwide in 2019, more than malaria and HIV, and WHO estimates that this figure will reach 10 million in 2050. Pseudomonas aeruginosa is one of the six most deadly pathogens1. With antibiotherapy research at its lowest, phage therapy is one of the most promising ways forward. The granting of a second patent in China just weeks after the first is the result of intense work by our intellectual property teams, who I would like to take this opportunity to wholeheartedly thank. The intellectual property policy is an integral part of our corporate strategy and aims to protect our investments in precision phage therapy, a therapeutic field of the future in which Pherecydes Pharma intends to play a leading role”.
Pherecydes Pharma has an active portfolio of four patents each covering multiple phages and their variants against the target bacteria: Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia Coli. These are three of the six most deadly bacteria. While some patents are still pending in certain jurisdictions, others have already been granted in major territories such as the United States, Europe, Japan, Australia, Hong Kong, Israel and China.